社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
Cheetah89
IP属地：未知
+关注
帖子 · 47
帖子 · 47
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
Cheetah89
Cheetah89
·
2021-08-06
Great
非常抱歉，此主贴已删除
看
1,447
回复
1
点赞
4
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-08-04
Fastastic
Most of Chinese stocks rally in premarket trading<blockquote>大多数中国股市在盘前交易中上涨</blockquote>
(Aug 4) Most of Chinese stocks rally in premarket trading.
Most of Chinese stocks rally in premarket trading<blockquote>大多数中国股市在盘前交易中上涨</blockquote>
看
2,347
回复
评论
点赞
2
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-07-28
Great
非常抱歉，此主贴已删除
看
1,706
回复
1
点赞
1
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-07-17
Right On
非常抱歉，此主贴已删除
看
2,713
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-07-12
Great outcome
非常抱歉，此主贴已删除
看
2,271
回复
1
点赞
3
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-07-09
Drop drop
U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>
July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can u
U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>
看
1,756
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-06-29
Good
Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.<blockquote>波音公司最新的喷气式飞机延误了。其他问题更为重要。</blockquote>
The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The
Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.<blockquote>波音公司最新的喷气式飞机延误了。其他问题更为重要。</blockquote>
看
1,845
回复
评论
点赞
2
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-06-27
Yes
非常抱歉，此主贴已删除
看
1,551
回复
2
点赞
2
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-06-24
Good
非常抱歉，此主贴已删除
看
1,271
回复
评论
点赞
1
编组 21备份 2
分享
举报
Cheetah89
Cheetah89
·
2021-06-24
Soon.
非常抱歉，此主贴已删除
看
1,938
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3583233379322937","uuid":"3583233379322937","gmtCreate":1620139355025,"gmtModify":1620612174940,"name":"Cheetah89","pinyin":"cheetah89","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":121,"tweetSize":47,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":893858390,"gmtCreate":1628256743410,"gmtModify":1631889786765,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/893858390","repostId":"1141271021","repostType":4,"isVote":1,"tweetType":1,"viewCount":1447,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":890335525,"gmtCreate":1628082648567,"gmtModify":1631889786768,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Fastastic","listText":"Fastastic","text":"Fastastic","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/890335525","repostId":"1138278557","repostType":4,"repost":{"id":"1138278557","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628069771,"share":"https://www.laohu8.com/m/news/1138278557?lang=zh_CN&edition=full","pubTime":"2021-08-04 17:36","market":"us","language":"en","title":"Most of Chinese stocks rally in premarket trading<blockquote>大多数中国股市在盘前交易中上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138278557","media":"Tiger Newspress","summary":"(Aug 4) Most of Chinese stocks rally in premarket trading.","content":"<p>(Aug 4) Most of Chinese stocks rally in premarket trading.</p><p><blockquote>（8月4日）大多数中国股市在盘前交易中上涨。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1e20b3f08685e4cdc45bf7c333cb5e6f\" tg-width=\"373\" tg-height=\"729\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Most of Chinese stocks rally in premarket trading<blockquote>大多数中国股市在盘前交易中上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMost of Chinese stocks rally in premarket trading<blockquote>大多数中国股市在盘前交易中上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-04 17:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(Aug 4) Most of Chinese stocks rally in premarket trading.</p><p><blockquote>（8月4日）大多数中国股市在盘前交易中上涨。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1e20b3f08685e4cdc45bf7c333cb5e6f\" tg-width=\"373\" tg-height=\"729\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138278557","content_text":"(Aug 4) Most of Chinese stocks rally in premarket trading.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2347,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801195664,"gmtCreate":1627486274458,"gmtModify":1631889786772,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/801195664","repostId":"1131233069","repostType":4,"isVote":1,"tweetType":1,"viewCount":1706,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":170778350,"gmtCreate":1626457946470,"gmtModify":1631889786775,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Right On","listText":"Right On","text":"Right On","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/170778350","repostId":"1130848269","repostType":4,"isVote":1,"tweetType":1,"viewCount":2713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":142018359,"gmtCreate":1626103495471,"gmtModify":1631889786777,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Great outcome","listText":"Great outcome","text":"Great outcome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/142018359","repostId":"2150539769","repostType":4,"isVote":1,"tweetType":1,"viewCount":2271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143375771,"gmtCreate":1625768448093,"gmtModify":1631889786780,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Drop drop ","listText":"Drop drop ","text":"Drop drop","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/143375771","repostId":"1184325113","repostType":4,"repost":{"id":"1184325113","kind":"news","pubTimestamp":1625750497,"share":"https://www.laohu8.com/m/news/1184325113?lang=zh_CN&edition=full","pubTime":"2021-07-08 21:21","market":"us","language":"en","title":"U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184325113","media":"Reuters","summary":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can u","content":"<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.</p><p><blockquote>路透7月8日-百健公司(Biogen Inc)表示，美国药品监管机构已缩小了可以使用其阿尔茨海默病药物的患者群体，此前该机构因上个月在没有证据证明对该疾病有明显益处的情况下批准该药物而招致尖锐批评。</blockquote></p><p> Shares of the company fell nearly 3% before the bell on Thursday.</p><p><blockquote>该公司股价周四盘前下跌近3%。</blockquote></p><p> The U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.</p><p><blockquote>美国。美国食品和药物管理局因决定允许Biogen的Aduhelm在患者中广泛使用而受到批评，尽管该公司仅在淀粉样脑斑块成分检测呈阳性的早期疾病患者中测试了该药物。</blockquote></p><p> Aduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.</p><p><blockquote>Aduhelm，也称为aducanumab，尽管缺乏明确的证据表明该药物有效，并且违背了外部顾问小组的建议，但仍获得批准。</blockquote></p><p> Several members of the FDA’s advisory panel have resigned in protest over the approval.</p><p><blockquote>FDA顾问小组的几名成员已经辞职，以抗议批准。</blockquote></p><p> Biogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.</p><p><blockquote>百健(Biogen)表示，在“与FDA、医生和患者权益倡导者对话”后，已要求更新标签（药物附带的书面信息）。百健(Biogen)在一份声明中表示：“其目的是帮助处方医生与患者互动。”</blockquote></p><p> The new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.</p><p><blockquote>新标签称，轻度认知障碍或轻度痴呆阶段的患者应开始使用该药物进行治疗。</blockquote></p><p> It also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.</p><p><blockquote>它还表示，没有关于在疾病早期或晚期开始治疗的安全性或有效性数据。</blockquote></p><p> The new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.</p><p><blockquote>Truist Securities分析师Robyn Karnauskas在一份报告中表示，新的患者群体在很大程度上符合该药物的预期使用方式。她预计到2031年销售额峰值约为120亿美元。</blockquote></p><p> Biogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.</p><p><blockquote>百健(Biogen)的药物受到了患者权益倡导者和一些渴望治疗这种记忆丧失疾病的神经科医生的欢迎。其他医生表示，临床试验结果不一致，需要更多证据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. FDA narrows patient group for Biogen's Alzheimer's drug<blockquote>美国FDA缩小百健阿尔茨海默病药物患者群体范围</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-07-08 21:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.</p><p><blockquote>路透7月8日-百健公司(Biogen Inc)表示，美国药品监管机构已缩小了可以使用其阿尔茨海默病药物的患者群体，此前该机构因上个月在没有证据证明对该疾病有明显益处的情况下批准该药物而招致尖锐批评。</blockquote></p><p> Shares of the company fell nearly 3% before the bell on Thursday.</p><p><blockquote>该公司股价周四盘前下跌近3%。</blockquote></p><p> The U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.</p><p><blockquote>美国。美国食品和药物管理局因决定允许Biogen的Aduhelm在患者中广泛使用而受到批评，尽管该公司仅在淀粉样脑斑块成分检测呈阳性的早期疾病患者中测试了该药物。</blockquote></p><p> Aduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.</p><p><blockquote>Aduhelm，也称为aducanumab，尽管缺乏明确的证据表明该药物有效，并且违背了外部顾问小组的建议，但仍获得批准。</blockquote></p><p> Several members of the FDA’s advisory panel have resigned in protest over the approval.</p><p><blockquote>FDA顾问小组的几名成员已经辞职，以抗议批准。</blockquote></p><p> Biogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.</p><p><blockquote>百健(Biogen)表示，在“与FDA、医生和患者权益倡导者对话”后，已要求更新标签（药物附带的书面信息）。百健(Biogen)在一份声明中表示：“其目的是帮助处方医生与患者互动。”</blockquote></p><p> The new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.</p><p><blockquote>新标签称，轻度认知障碍或轻度痴呆阶段的患者应开始使用该药物进行治疗。</blockquote></p><p> It also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.</p><p><blockquote>它还表示，没有关于在疾病早期或晚期开始治疗的安全性或有效性数据。</blockquote></p><p> The new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.</p><p><blockquote>Truist Securities分析师Robyn Karnauskas在一份报告中表示，新的患者群体在很大程度上符合该药物的预期使用方式。她预计到2031年销售额峰值约为120亿美元。</blockquote></p><p> Biogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.</p><p><blockquote>百健(Biogen)的药物受到了患者权益倡导者和一些渴望治疗这种记忆丧失疾病的神经科医生的欢迎。其他医生表示，临床试验结果不一致，需要更多证据。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.reuters.com/article/biogen-alzheimers-fda/update-2-u-s-fda-narrows-patient-group-for-biogens-alzheimers-drug-idUSL3N2OK2XT","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184325113","content_text":"July 8 (Reuters) - Biogen Inc said the U.S. drug regulator has narrowed the patient group that can use its Alzheimer’s disease drug, after the agency drew sharp criticism for approving the drug last month without proof of clear benefit against the disease.\nShares of the company fell nearly 3% before the bell on Thursday.\nThe U.S. Food and Drug Administration has been criticized for its decision to allow wide use of Biogen’s Aduhelm among patients even though the company had tested the drug only in patients with early disease who tested positive for a component of amyloid brain plaques.\nAduhelm, also known as aducanumab, was approved despite a lack of clear evidence showing the drug worked and against the advice of an outside group of advisers.\nSeveral members of the FDA’s advisory panel have resigned in protest over the approval.\nBiogen said it had asked for an update to the label, a written information that accompanies a drug, after “dialogue with FDA, physicians and patient advocates.” “The intent is to help prescribing physicians to engage with patients,” Biogen said in a statement.\nThe new label says that treatment with the drug should be initiated in patients with mild cognitive impairment or mild dementia stage of the disease.\nIt also says there is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.\nThe new patient population is largely in-line with how the drug was expected to be used, Truist Securities analyst Robyn Karnauskas said in a note. She expects roughly $12 billion in peak sales by 2031.\nBiogen’s drug has been hailed by patient advocates and some neurologists eager for a treatment for the memory-robbing disease. Other doctors said clinical trial results were inconsistent and more proof was needed.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":1756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":150669022,"gmtCreate":1624896535366,"gmtModify":1631889786785,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/150669022","repostId":"1184667820","repostType":4,"repost":{"id":"1184667820","kind":"news","pubTimestamp":1624890163,"share":"https://www.laohu8.com/m/news/1184667820?lang=zh_CN&edition=full","pubTime":"2021-06-28 22:22","market":"us","language":"en","title":"Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.<blockquote>波音公司最新的喷气式飞机延误了。其他问题更为重要。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184667820","media":"Barrons","summary":"The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The ","content":"<p>The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The Federal Aviation Administration told the company recently the jet likely won’t be approved for commercial service until mid-2023.</p><p><blockquote>商业航空航天巨头波音公司收到了一些关于其最新777喷气式飞机777X的坏消息。美国联邦航空管理局最近告诉该公司，这架飞机可能要到2023年中期才会被批准投入商业服务。</blockquote></p><p> That timeline, contained in a May letter from the regulator to the company, is longer than investors might have expected, but it isn’t actually all that bad for the stock. Boeing didn’t immediately reply to a request for comment.</p><p><blockquote>监管机构5月份致该公司的一封信中包含的时间表比投资者预期的要长，但实际上对该股来说并没有那么糟糕。波音公司没有立即回复置评请求。</blockquote></p><p> The 777X took its maiden test flight back in January 2020. That might have put it on track to be approved by mid-2021, based on the way the industry worked a few years ago. Consider that the 737 MAX jet took its initial flight in early 2016 and was approved for service about 14 months later. Deliveries began around mid-2017.</p><p><blockquote>777X于2020年1月进行了首次试飞。根据该行业几年前的运作方式，这可能会使其有望在2021年中期获得批准。考虑到737 MAX喷气式飞机于2016年初首飞，并在大约14个月后获准服役。交付于2017年中期左右开始。</blockquote></p><p> But the MAX, of course, was grounded in March 2019 following two deadly crashes within five months. It took 20-plus months of design modifications, additional testing, and regulatory oversight, for Boeing to win permission for the jet to carry passengers again.</p><p><blockquote>但MAX在五个月内发生两起致命事故后，于2019年3月停飞。波音公司花了20多个月的设计修改、额外测试和监管监督，才获得该飞机再次载客的许可。</blockquote></p><p> The MAX situation caused changes at Boeing, including new safety committees, as well as alterations to the FAA’s oversight process. Those shifts could be stretching out the approval process for new planes. The pandemic probably didn’t help the 777x approval timeline either.</p><p><blockquote>MAX的情况引起了波音公司的变化，包括新的安全委员会，以及美国联邦航空局监督流程的改变。这些转变可能会延长新飞机的审批流程。疫情可能也没有帮助777x的批准时间表。</blockquote></p><p> Regardless of the reasons, the approval process has been slow. Boeing investors aren’t thrilled with news of the delay, although deliveries of MAX jets and the recovery of the commercial aerospace business are bigger concerns. Shares were down about 2.8% at $241.56 in early trading, while the S&P 500 and Dow Jones Industrial Average were nearly flat.</p><p><blockquote>不管是什么原因，审批过程一直很慢。波音投资者对延误的消息并不感到兴奋，尽管MAX喷气式飞机的交付和商业航空航天业务的复苏是更大的担忧。早盘股价下跌约2.8%，至241.56美元，而标准普尔500指数和道琼斯工业平均指数几乎持平。</blockquote></p><p> Vertical Research Partners analyst Rob Stallard summed up all of the positives and negatives for Boeing in a Monday report. The 777X delay is a regulatory problem, but it is only one of three he mentioned. China, for instance, hasn’t reapproved the 737 MAX yet, and the 787 still faces some reviews.</p><p><blockquote>Vertical Research Partners分析师Rob Stallard在周一的一份报告中总结了波音公司的所有积极和消极因素。777X延迟是一个监管问题，但这只是他提到的三个问题之一。例如，中国尚未重新批准737 MAX，787仍面临一些审查。</blockquote></p><p> On the positive side of the equation, new orders for the 737 MAX are starting to come in. He expects United Airlines(UAL) to announce an order for about 100 MAX jets in coming days.</p><p><blockquote>从积极的一面来看，737 MAX的新订单开始到来。他预计联合航空（UAL）将在未来几天宣布约100架MAX喷气式飞机的订单。</blockquote></p><p> The “roller coaster ride continues” for Boeing stock, he said, noting that “this week’s events probably don’t have an immediate impact on our numbers.” His target price for Boeing stock remains $242 a share. He rates shares at Hold.</p><p><blockquote>他表示，波音股票的“过山车之旅仍在继续”，并指出“本周的事件可能不会对我们的数据产生直接影响。”他对波音股票的目标价仍为每股242美元。他将股票评级为持有。</blockquote></p><p> Stallard is a little more bearish than his peers. Overall, about 57% of analysts covering the stock rate the shares at Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%. The averageprice targetamong analysts is about $267.</p><p><blockquote>斯塔拉德比他的同行更悲观一些。总体而言，约57%的分析师将该股评级为买入。标普500股票的平均买入评级比率约为55%。分析师的平均目标价约为267美元。</blockquote></p><p> The biggest issue facing the entire commercial aerospace industry is postpandemic demand. June 2021 U.S. commercial air travel is down roughly 25% compared with 2019 levels. But it is up almost 300% compared with June 2020.</p><p><blockquote>整个商业航天行业面临的最大问题是大流行后的需求。与2019年相比，2021年6月美国商业航空旅行下降了约25%。但与2020年6月相比，上涨了近300%。</blockquote></p><p> Things are slowly getting better for the industry. United Airlines, for instance, said Monday it expects a profit in July. It would be the airline’s first monthly profit since January 2020.</p><p><blockquote>该行业的情况正在慢慢好转。例如，联合航空周一表示，预计7月份将实现盈利。这将是该航空公司自2020年1月以来首次实现月度盈利。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boeing’s Newest Jet Is Delayed. Other Issues Are More Important.<blockquote>波音公司最新的喷气式飞机延误了。其他问题更为重要。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoeing’s Newest Jet Is Delayed. Other Issues Are More Important.<blockquote>波音公司最新的喷气式飞机延误了。其他问题更为重要。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-06-28 22:22</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The Federal Aviation Administration told the company recently the jet likely won’t be approved for commercial service until mid-2023.</p><p><blockquote>商业航空航天巨头波音公司收到了一些关于其最新777喷气式飞机777X的坏消息。美国联邦航空管理局最近告诉该公司，这架飞机可能要到2023年中期才会被批准投入商业服务。</blockquote></p><p> That timeline, contained in a May letter from the regulator to the company, is longer than investors might have expected, but it isn’t actually all that bad for the stock. Boeing didn’t immediately reply to a request for comment.</p><p><blockquote>监管机构5月份致该公司的一封信中包含的时间表比投资者预期的要长，但实际上对该股来说并没有那么糟糕。波音公司没有立即回复置评请求。</blockquote></p><p> The 777X took its maiden test flight back in January 2020. That might have put it on track to be approved by mid-2021, based on the way the industry worked a few years ago. Consider that the 737 MAX jet took its initial flight in early 2016 and was approved for service about 14 months later. Deliveries began around mid-2017.</p><p><blockquote>777X于2020年1月进行了首次试飞。根据该行业几年前的运作方式，这可能会使其有望在2021年中期获得批准。考虑到737 MAX喷气式飞机于2016年初首飞，并在大约14个月后获准服役。交付于2017年中期左右开始。</blockquote></p><p> But the MAX, of course, was grounded in March 2019 following two deadly crashes within five months. It took 20-plus months of design modifications, additional testing, and regulatory oversight, for Boeing to win permission for the jet to carry passengers again.</p><p><blockquote>但MAX在五个月内发生两起致命事故后，于2019年3月停飞。波音公司花了20多个月的设计修改、额外测试和监管监督，才获得该飞机再次载客的许可。</blockquote></p><p> The MAX situation caused changes at Boeing, including new safety committees, as well as alterations to the FAA’s oversight process. Those shifts could be stretching out the approval process for new planes. The pandemic probably didn’t help the 777x approval timeline either.</p><p><blockquote>MAX的情况引起了波音公司的变化，包括新的安全委员会，以及美国联邦航空局监督流程的改变。这些转变可能会延长新飞机的审批流程。疫情可能也没有帮助777x的批准时间表。</blockquote></p><p> Regardless of the reasons, the approval process has been slow. Boeing investors aren’t thrilled with news of the delay, although deliveries of MAX jets and the recovery of the commercial aerospace business are bigger concerns. Shares were down about 2.8% at $241.56 in early trading, while the S&P 500 and Dow Jones Industrial Average were nearly flat.</p><p><blockquote>不管是什么原因，审批过程一直很慢。波音投资者对延误的消息并不感到兴奋，尽管MAX喷气式飞机的交付和商业航空航天业务的复苏是更大的担忧。早盘股价下跌约2.8%，至241.56美元，而标准普尔500指数和道琼斯工业平均指数几乎持平。</blockquote></p><p> Vertical Research Partners analyst Rob Stallard summed up all of the positives and negatives for Boeing in a Monday report. The 777X delay is a regulatory problem, but it is only one of three he mentioned. China, for instance, hasn’t reapproved the 737 MAX yet, and the 787 still faces some reviews.</p><p><blockquote>Vertical Research Partners分析师Rob Stallard在周一的一份报告中总结了波音公司的所有积极和消极因素。777X延迟是一个监管问题，但这只是他提到的三个问题之一。例如，中国尚未重新批准737 MAX，787仍面临一些审查。</blockquote></p><p> On the positive side of the equation, new orders for the 737 MAX are starting to come in. He expects United Airlines(UAL) to announce an order for about 100 MAX jets in coming days.</p><p><blockquote>从积极的一面来看，737 MAX的新订单开始到来。他预计联合航空（UAL）将在未来几天宣布约100架MAX喷气式飞机的订单。</blockquote></p><p> The “roller coaster ride continues” for Boeing stock, he said, noting that “this week’s events probably don’t have an immediate impact on our numbers.” His target price for Boeing stock remains $242 a share. He rates shares at Hold.</p><p><blockquote>他表示，波音股票的“过山车之旅仍在继续”，并指出“本周的事件可能不会对我们的数据产生直接影响。”他对波音股票的目标价仍为每股242美元。他将股票评级为持有。</blockquote></p><p> Stallard is a little more bearish than his peers. Overall, about 57% of analysts covering the stock rate the shares at Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%. The averageprice targetamong analysts is about $267.</p><p><blockquote>斯塔拉德比他的同行更悲观一些。总体而言，约57%的分析师将该股评级为买入。标普500股票的平均买入评级比率约为55%。分析师的平均目标价约为267美元。</blockquote></p><p> The biggest issue facing the entire commercial aerospace industry is postpandemic demand. June 2021 U.S. commercial air travel is down roughly 25% compared with 2019 levels. But it is up almost 300% compared with June 2020.</p><p><blockquote>整个商业航天行业面临的最大问题是大流行后的需求。与2019年相比，2021年6月美国商业航空旅行下降了约25%。但与2020年6月相比，上涨了近300%。</blockquote></p><p> Things are slowly getting better for the industry. United Airlines, for instance, said Monday it expects a profit in July. It would be the airline’s first monthly profit since January 2020.</p><p><blockquote>该行业的情况正在慢慢好转。例如，联合航空周一表示，预计7月份将实现盈利。这将是该航空公司自2020年1月以来首次实现月度盈利。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/faa-delay-boeing-777x-jet-stock-51624889202?mod=hp_LATEST\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BA":"波音"},"source_url":"https://www.barrons.com/articles/faa-delay-boeing-777x-jet-stock-51624889202?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184667820","content_text":"The commercial aerospace giant Boeing got a bit of bad news about its latest 777 jet, the 777X. The Federal Aviation Administration told the company recently the jet likely won’t be approved for commercial service until mid-2023.\nThat timeline, contained in a May letter from the regulator to the company, is longer than investors might have expected, but it isn’t actually all that bad for the stock. Boeing didn’t immediately reply to a request for comment.\nThe 777X took its maiden test flight back in January 2020. That might have put it on track to be approved by mid-2021, based on the way the industry worked a few years ago. Consider that the 737 MAX jet took its initial flight in early 2016 and was approved for service about 14 months later. Deliveries began around mid-2017.\nBut the MAX, of course, was grounded in March 2019 following two deadly crashes within five months. It took 20-plus months of design modifications, additional testing, and regulatory oversight, for Boeing to win permission for the jet to carry passengers again.\nThe MAX situation caused changes at Boeing, including new safety committees, as well as alterations to the FAA’s oversight process. Those shifts could be stretching out the approval process for new planes. The pandemic probably didn’t help the 777x approval timeline either.\nRegardless of the reasons, the approval process has been slow. Boeing investors aren’t thrilled with news of the delay, although deliveries of MAX jets and the recovery of the commercial aerospace business are bigger concerns. Shares were down about 2.8% at $241.56 in early trading, while the S&P 500 and Dow Jones Industrial Average were nearly flat.\nVertical Research Partners analyst Rob Stallard summed up all of the positives and negatives for Boeing in a Monday report. The 777X delay is a regulatory problem, but it is only one of three he mentioned. China, for instance, hasn’t reapproved the 737 MAX yet, and the 787 still faces some reviews.\nOn the positive side of the equation, new orders for the 737 MAX are starting to come in. He expects United Airlines(UAL) to announce an order for about 100 MAX jets in coming days.\nThe “roller coaster ride continues” for Boeing stock, he said, noting that “this week’s events probably don’t have an immediate impact on our numbers.” His target price for Boeing stock remains $242 a share. He rates shares at Hold.\nStallard is a little more bearish than his peers. Overall, about 57% of analysts covering the stock rate the shares at Buy. The average Buy-rating ratio for stocks in the S&P 500 is about 55%. The averageprice targetamong analysts is about $267.\nThe biggest issue facing the entire commercial aerospace industry is postpandemic demand. June 2021 U.S. commercial air travel is down roughly 25% compared with 2019 levels. But it is up almost 300% compared with June 2020.\nThings are slowly getting better for the industry. United Airlines, for instance, said Monday it expects a profit in July. It would be the airline’s first monthly profit since January 2020.","news_type":1,"symbols_score_info":{"BA":0.9}},"isVote":1,"tweetType":1,"viewCount":1845,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124306062,"gmtCreate":1624726385356,"gmtModify":1631889786789,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Yes ","listText":"Yes ","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/124306062","repostId":"1164137597","repostType":4,"isVote":1,"tweetType":1,"viewCount":1551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":126375104,"gmtCreate":1624546234208,"gmtModify":1631889786790,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/126375104","repostId":"1120000038","repostType":4,"isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121223339,"gmtCreate":1624466310121,"gmtModify":1631889786795,"author":{"id":"3583233379322937","authorId":"3583233379322937","name":"Cheetah89","avatar":"https://static.tigerbbs.com/b8db55ea74f4f68571d2b242a705a50b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583233379322937","authorIdStr":"3583233379322937"},"themes":[],"htmlText":"Soon. ","listText":"Soon. ","text":"Soon.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121223339","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":1938,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}